MariMed (OTCMKTS:MRMD) Posts Quarterly Earnings Results, Meets Expectations

MariMed (OTCMKTS:MRMD) announced its earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01), Zacks reports. The company had revenue of $41.92 million for the quarter, compared to analysts’ expectations of $39.80 million. MariMed had a negative return on equity of 10.33% and a negative net margin of 9.13%.

MariMed Stock Up 1.4%

OTCMKTS MRMD opened at $0.07 on Friday. The stock has a market capitalization of $26.08 million, a P/E ratio of -1.62 and a beta of 1.33. MariMed has a 52 week low of $0.06 and a 52 week high of $0.23. The company has a debt-to-equity ratio of 1.67, a quick ratio of 0.34 and a current ratio of 0.95. The stock has a fifty day moving average of $0.07 and a 200-day moving average of $0.08.

MariMed Company Profile

MariMed Inc is a multi?state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult?use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre?rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.